Meet us at BIO-Europe 2025
We’re looking forward to participating at BIO-Europe 2025, taking place in Vienna on November 3–5.
Learn more
Comprehensive characterization of the rat magnetic microbead model
Glaucoma is a leading cause of irreversible blindness, highlighting the urgent need for reliable preclinical models that capture both structural and functional disease aspects. Our recently published study by Kernius Mickevičius provides a longitudinal evaluation of the rat magnetic microbead model of ocular hypertension by combining multimodal monitoring tools including spectral-domain optical coherence tomography (SD-OCT), pattern electroretinography (pERG), optomotor testing, and morphological analysis.
Learn more
Welfare complications in the male BN/Crl and RjHan:SD rat streptozotocin-induced diabetes models
Our latest publication by Anni Tenhunen and colleagues on the welfare outcomes of two widely used rat lines, Brown Norway (BN/Crl) and Sprague Dawley (RjHan:SD), in the STZ-induced diabetic retinopathy model. BN/Crl rats are often favored for ocular studies due to their pigmented eyes, however, our study raises important concerns about their routine use in diabetic models, given their increased risk of serious welfare issues.
Learn more
Life Sciences Baltics 2025
Come to meet us on our home turf in Vilnius! We are pleased to invite you to visit our booth at Life Sciences Baltics 2025 taking place on September 17–18 in Vilnius, Lithuania.
Learn more
Faster results for in vitro corneal permeability studies
At Experimentica, we are committed to advancing R&D and continuously improving established study methods. Our work is guided by three core principles: quality, flexibility, and scientific excellence, all of which support our commitment to be a trusted partner for our clients. In collaboration with Finnadvance Ltd, we validated the AKITA® platform combined with human corneal epithelial cells which has yielded substantial advancements in in vitro corneal permeability studies.
Learn more
Experimentica Appoints Dr. Artem Shatillo as Director, Digital Transformation
Experimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is excited to announce the appointment of Dr. Artem Shatillo as Director of Digital Transformation, effective July 1, 2025.
Learn more
FELASA 2025 presentation: Assessing lidocaine-based analgesia for mouse ear notching: Insights into strain-specific reactions
From the beginning of 2024, a new national law on animal protection in Finland (1165/2023 3 §) requires laboratory rodent ear notching to be performed only with "appropriate pain relief". However, the European Union directive on the protection of animals used for scientific purposes (2010/63/EU) classifies ear notching as a routine identification method rather than a procedure, leaving no specific guidelines on suitable analgesia at the EU or the national level. This study aimed to evaluate the suitability of a lidocaine-based cream as analgesia (EMLA cream 5%, lidocaine + prilocaine 25+25 mg/g, Aspen Pharmacare Australia) for mice undergoing ear notching.
Learn more
Experimentica presents at FELASA 2025
At Experimentica, animal welfare is a core principle of our work. We are dedicated to include refinement studies as part of our internal R&D to improve the well-being of animals involved.
Learn more
ARVO 2025 presentation: Morphological, functional, and behavioral alterations in a microbead-induced mouse glaucoma model
The main aim of the study was to examine the correlation of ocular hypertension with morphological, functional and behavioural parameters in the mouse magnetic microbead glaucoma model.
Learn more
ARVO 2025 presentation: Combined administration of BDNF and CNTF provides superior neuroprotection as compared to BDNF alone in a mouse optic nerve crush model
Glaucoma, a leading cause of blindness and visual impairment worldwide, is characterized by progressive loss of retinal ganglion cells (RGCs) and damage to the optic nerve. Neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), have been extensively studied for their potential to promote RGC survival and axonal regeneration. However, BDNF's efficacy is restricted by receptor desensitization, while CNTF alone often induces inflammation and gliosis, limiting its therapeutic potential. This study was aimed at evaluating if a combination of BDNF and CNTF offers synergistic effects, providing superior neuroprotection as compared to either factor alone.
Learn more
